Description
Copanlisib, marketed under the brand name ALIQOPA, It is an prescription medication that has been approved copanlisib (Aliqopa) on September 14, 2017 for the treatment of adult patients with relapsed follicular lymphoma. The FDA granted the approval under its accelerated approval regulations.
What is ALIQOPA (Copanlisib) ?
ALIQOPA is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Accelerated approval was granted for this indication based on overall response rate.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Source Content From US FDA
How to order approved “ALIQOPA (Copanlisib) for Injection” Medicine?
ALIQOPA (Copanlisib) Injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing ALIQOPA and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
